Shares of RxSight Inc. (RXST) are up over 20% at $49 in premarket trading, following strong second-quarter results and upbeat outlook for the year.
RxSight is a commercial-stage medical technology company providing light adjustable intraocular lens for post-cataract surgery patients. The company markets FDA-approved proprietary RxSight Light Adjustable Lens system, which consists of Light Adjustable Lens (LAL), Light Delivery Device (LDD) and accessories.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com